论文部分内容阅读
小儿慢性肾功能不全最重要的并发症是肾性贫血和生长发育障碍。最近生物技术在医学上的应用有了令人瞩目的进展,给慢性肾功能不全患带来了福音。现就其中的促红细胞生成素、生长激素及粒细胞集落刺激因子在小儿科领域内的治疗效果和展望加以论述。一、重组人促红细胞生成素(rhEpo)在肾性贫血中的应用成人透析患者肾性贫血时常用蛋白同化激素,但用于小儿有导致骨骺线早期愈合之虞,故不宜轻易使用。因此慢性肾功能不全患儿多需频繁输血,而输血也有各种副作用,有时能使组织相容抗原致敏而造成肾移植的困难。1987年小儿EPO研讨会报道平均10.6岁的42例透析患儿使用rhEPO25～75u/kg,每周2～3次共3个月,其中28例(66.6%)Hb显著提高,增加了1.5g/
The most important complication of childhood chronic renal insufficiency is renal anemia and growth and development disorders. The recent medical application of biotechnology has made remarkable progress, bringing the gospel to chronic renal insufficiency. Now on the erythropoietin, growth hormone and granulocyte colony stimulating factor in pediatric field treatment effect and prospect are discussed. First, the application of recombinant human erythropoietin (rhEpo) in renal anemia Adult dialysis patients often use protein anabolic hormones, but for children with epiphyseal line lead to the early healing of the danger, it should not be easy to use. Therefore, children with chronic renal insufficiency need frequent transfusions, and transfusions also have various side effects, and sometimes make tissue-compatible antigen sensitization caused by renal transplantation difficulties. 1987 pediatric EPO seminar reported an average of 10.6 years old 42 dialysis patients with rhEPO25 ~ 75u / kg, 2 to 3 times a week for a total of 3 months, of which 28 cases (66.6%) Hb significantly increased, an increase of 1.5g /